Can SARS-CoV antibodies be used to develop universal coronavirus vaccines?

By Samantha Black, PhD, The Science Advisory Board editor in chief

October 12, 2020 -- Can antibodies developed against SARS-CoV during the 2003 outbreak be used to prevent infection by SARS-CoV-2? In an October 9 study published in Science Advances, researchers analyzed precious serum collected from convalescent SARS-CoV patients to find out.

SARS-CoV-2 is genetically close to SARS-CoV, which emerged in 2002. Like SARS-CoV and many other coronaviruses, SARS-CoV-2 utilizes its surface spike glycoprotein to gain entry into host cells. Each unit of the spike trimer contains an S1 and S2 subunit, with the N-terminal S1 subunit binding to cellular receptor angiotensin-converting enzyme 2 (ACE2) through an internal receptor-binding domain (RBD).

SARS-CoV-2 and SARS-CoV share around 80% homology in full-length genome sequences, and the spike proteins share about 76% amino acid identity. Moreover, the RBD sequences are only around 74% identical, with most mutations occurring in the RBD region. These changes in the SARS-CoV-2 RBD have led to 10- to 20-fold higher ACE2 binding affinity compared to SARS-CoV, which could explain the higher transmissibility of SARS-CoV-2.

Structure determination has previously revealed that SARS-CoV-2 RBD binds ACE2 in the same orientation as the SARS-CoV RBD and relies on conserved, mostly aromatic, residues. This suggests that the mechanism of infection is conserved among Coronaviridae.

During the 2003 outbreak of SARS-CoV, researchers began development of vaccines and neutralizing antibodies that target the SARS-CoV RBD. In this paper, a group of Chinese researchers sought to explore the antigenic cross-reactivity between SARS-CoV-2 and SARS-CoV.

The researchers, who were directly involved in studies conducted during the 2003 outbreak, evaluated immune sera collected from 20 recovered SARS-CoV patients that were enrolled in a SARS-CoV follow-up study at the Peking Union Medical College Hospital, Beijing. The samples were collected three to six months after discharge and stored in aliquots at -80°C.

All of these patients displayed high titers of antibodies against the S1 subunit and RBD proteins of SARS-CoV and cross-reacted strongly with the spike protein of SARS-CoV-2. However, they found that each serum sample had lower efficiency in inhibiting SARS-CoV-2 compared to SARS-CoV. Specifically, the patient samples had higher reactivity with the S2 subunit of SARS-CoV-2 relative to the S1 subunit and RBD protein.

When developing vaccines and therapies that are effective against multiple strains of coronaviruses, it is important to test each candidates' cross-reactivity potential. The literature and evidence available for polyclonal antibodies from various immunized animals is inconsistent. Some studies suggested that SARS-CoV RBD antibodies could be used to develop a vaccine that is effective against both SARS-CoV and SARS-CoV-2, while other evidence points to the inability of SARS-CoV-derived antibodies to neutralize SARS-CoV-2 infection.

Using a pseduovirus-based neutralization assay, the researchers tested panels of antisera against SARS-CoV spike and RBD proteins for their ability to cross-react and cross-neutralize SARS-CoV and SARS-CoV-2. They found that RBD proteins derived from different SARS-CoV strains can elicit antibodies with unique functionalities. Some proteins derived from palm civet SARS-CoV induced antibodies capable of blocking the RBD-receptor binding, while others derived from human strains did not. Verification in a mouse model immunized with RBD-Fc fusion protein encoding the palm civet SARS-CoV strain found that the sera cross-reacted well with the spike protein of SARS-CoV-2, suggesting that SARS-CoV and SARS-CoV-2 share conserved epitopes in their respective RBD sites.

According to the authors, these results prompt interesting questions for future research including:

  • Whether individuals who recovered from previous SARS-CoV infection can recall immunity against SARS-CoV-2
  • Whether a universal vaccine can be rationally designed by engineering the spike protein RBD sequences

They also noted that although antibody-dependent enhancement (when antibody binding to a virus actually eases its entry into host cells) was not observed in this study, the effect should be addressed in current and future vaccine development efforts.

Do you have a unique perspective on your research related to virology or vaccine development? Contact the editor today to learn more.

---



Long-lasting IgG antibodies found in blood and saliva of COVID-19 patients
Researchers have discovered that immunoglobulin G (IgG) antibodies to the SARS-CoV-2 virus are longer lasting in the blood and saliva of COVID-19 patients...
SARS-CoV mAb shown to block SARS-CoV-2
Antibodies from recovered SARS-CoV patients appear to block SARS-CoV-2 infectivity and could help in the development of antiviral treatments or vaccines,...
Chinese researchers mobilize to classify 2019-nCoV
In response to a recent outbreak of the novel coronavirus (2019-CoV), scientists in China have uncovered genetic similarities with severe acute respiratory...

Copyright © 2020 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter